IFNA1 and Hand-foot syndrome: From the adverse events reported in these trials, the safety profile of both interventions appears to be comparable with IFN, with some adverse events particularly associated with bevacizumab plus IFN (proteinuria, hypertension, bleeding events) and some with sunitinib treatment (hypertension, hand and foot syndrome and diarrhoea).